
Aktiviere Job-Benachrichtigungen per E-Mail!
Erstelle in nur wenigen Minuten einen maßgeschneiderten Lebenslauf
Überzeuge Recruiter und verdiene mehr Geld. Mehr erfahren
A leading research institution in Lübeck is offering a PhD position focusing on the translation of evolutionary principles into antimicrobial treatment. This role involves researching antibiotic resistance, screening and optimizing antibiotic combinations for urinary tract infections, and requires a Master's in life sciences with research experience in microbiology. The position provides a vibrant academic environment and is limited until March 31, 2029. Applications are welcomed until February 13, 2026.
Kiel
Antibiotic resistance develops through natural selection and genetic drift in bacterial populations, representing an inevitable outcome of adaptive evolution under antibiotic pressure. While responsible antibiotic use can slow this process, it cannot prevent it entirely. A deeper understanding of bacterial evolutionary pathways and the ecological and physiological consequences of resistance is essential for developing sustainable therapeutic strategies.
This doctoral project aims to address antibiotic resistance in urinary tract infections (UTIs) by screening and optimizing antibiotic combinations. The work will integrate evolutionary principles and their quantitative readouts into comprehensive evaluation frameworks to ensure long-lasting therapeutic efficacy against both sensitive and multidrug-resistant Uropathogenic Escherichia coli (UPEC) strains. Using UTIs in hospitalized patients as a clinical use case, the project will translate in vitro results into clinical recommendations.
The position is based in Lübeck, an attractive university town offering a vibrant academic community, diverse cultural life, and excellent quality of life. With a dynamic student scene, charming historic center, and the Baltic Sea just a short trip away, Lübeck provides an ideal setting for pursuing a PhD.
We invite applications for a doctoral researcher starting 1 April 2026, to join our team as part of a newly established junior research group, and contribute to advancing evolution-informed antibiotic therapy. The position is initially limited until 31 March 2029.
We look forward to receiving your application by 13 February 2026, quoting our job advertisement number 27900.